How tifacogin could not Captivate severe community-acquired pneumonia

American Journal of Respiratory and Critical Care Medicine

Volumn 183, Issue 11, 2011, Pages 1449-1450

  Sanchez, Juan F ^a   Le, Long ^a   Arroliga, Alejandro C ^a  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTIFICIAL VENTILATION; COMMUNITY ACQUIRED PNEUMONIA; EDITORIAL; INTENSIVE CARE; PRIORITY JOURNAL; SEPSIS;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PNEUMONIA; PROTEINS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79957963193     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201103-0407ED     Document Type: Editorial

References (13)

1. Niederman MS. Community-acquired pneumonia: the US perspective. Semin Respir Crit Care Med 2009;30:179-188.
2. National Center for Health Statistics. Health, United States, 2006, with chartbook on trends in the health of Americans (accessed January 17, 2007). Available from: http://www.cdc.gov/nchs/data/hus/hus06.pdf.
3. Jackson ML, Neuzil KM, Thompson WW, Shay DK, Yu O, Hanson CA, Jackson LA. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004;39: 1642-1650. (Pubitemid 39578539)
4. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associated costs of care. Crit Care Med 2001;29:1303-1310. (Pubitemid 32641789)
5. Angus DC, Crowther MA. Unraveling severe sepsis: why did OPTIMIST fail and what's next? JAMA 2003;290:256-258.
6. Aird WC. Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis. Crit Care Med 2001;29:s28-s34.
7. Doshi SN, Marmur JD. Evolving role of tissue factor and its pathway inhibitor. Crit Care Med 2002;30:S242-S250.
8. Riewald M, Wolfram R. Orchestration of coagulation protease signaling by tissue factor. Trends Cardiovasc Med 2002;12:149-154. (Pubitemid 34586818)
9. Abraham E, Reinhart K, Opan S, Demeyer I, Doig C, Lopez Rodriguez A, Bcale R, Svoboda P, Laterre PF, Simon S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003;290:238-247. (Pubitemid 37430063)
10. Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med 2000;28:S31-S33.
11. Laterre PF. Beyond antibiotics in severe community-acquired pneumonia: the role and rationale for tissue factor pathway inhibition. Crit Care 2008;12:S4-S9.
12. Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Otero Vidal L, Lobo SM, San Juan J, Hwang SC, Dugernier T,et al. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2011;183:1561-1568.
13. Ferrer R, Artigas A, Levy MM, Blanco J, Gonzalez-Diaz G, Garnacho-Montero J, Ibanez J, Palencia E, Quintana M, Torre-Prados MV. Improvement in process of carfe and outcome after a multicenter severe sepsis educational program in Spain. JAMA 2008;299:2294-2303. (Pubitemid 351724396)